| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $105,714,683 | 50 | 100 |
| Apuli Maricel | Chief Accounting Officer | 0 | $0 | 6 | $767,398 | $-767,398 |
| Scott Randal W. | director | 0 | $0 | 3 | $2.09M | $-2.09M |
| Trimarchi Thomas | President and CFO | 0 | $0 | 3 | $3.03M | $-3.03M |
| DANIELS RONALD J | director | 0 | $0 | 1 | $3.89M | $-3.89M |
| Valantine Hannah | director | 0 | $0 | 5 | $4.37M | $-4.37M |
| Ellis Andrea | director | 0 | $0 | 2 | $5.65M | $-5.65M |
| Lo Andrew | director | 0 | $0 | 2 | $6.32M | $-6.32M |
| Cook Jennifer E. | director | 0 | $0 | 4 | $21.92M | $-21.92M |
| Kumar Neil | Chief Executive Officer | 0 | $0 | 24 | $57.68M | $-57.68M |
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin …
Over the last 12 months, insiders at BridgeBio Pharma, Inc. have bought $0 and sold $105.71M worth of BridgeBio Pharma, Inc. stock.
On average, over the past 5 years, insiders at BridgeBio Pharma, Inc. have bought $2.49M and sold $219.14M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 12,000 shares for transaction amount of $100,680 was made by Ellis Andrea () on 2022‑03‑15.
| 2026-10-30 | Sale | Apuli Maricel | Chief Accounting Officer | 2,000 0.001% | $72.85 | $145,700 | ||
| 2026-09-17 | Sale | Kumar Neil | Chief Executive Officer | 10,000 0.0052% | $69.08 | $690,847 | -0.59% | |
| 2026-08-19 | Sale | Kumar Neil | Chief Executive Officer | 10,000 0.0051% | $84.03 | $840,257 | -18.64% | |
| 2026-08-18 | Sale | Kumar Neil | Chief Executive Officer | 34,980 0.0178% | $82.53 | $2.89M | -17.64% | |
| 2026-07-30 | Sale | Apuli Maricel | Chief Accounting Officer | 2,000 0.001% | $80.06 | $160,120 | -11.88% | |
| 2026-07-09 | Sale | Ellis Andrea | director | 17,167 0.0082% | $84.00 | $1.44M | -16.60% | |
| 2026-07-09 | Sale | Cook Jennifer E. | director | 148,589 0.0745% | $88.54 | $13.16M | -16.60% | |
| 2026-06-24 | Sale | Cook Jennifer E. | director | 37,167 0.0194% | $70.00 | $2.6M | +8.42% | |
| 2026-06-23 | Sale | Valantine Hannah | director | 2,196 0.0011% | $68.57 | $150,580 | +9.27% | |
| 2026-06-23 | Sale | Cook Jennifer E. | director | 2,196 0.0011% | $68.57 | $150,580 | +9.27% | |
| 2026-06-22 | Sale | Valantine Hannah | director | 2,808 0.0014% | $68.00 | $190,944 | +8.78% | |
| 2026-06-15 | Sale | Cook Jennifer E. | director | 90,240 0.0451% | $66.62 | $6.01M | +10.00% | |
| 2026-06-05 | Sale | Kumar Neil | Chief Executive Officer | 40,000 0.0205% | $67.88 | $2.72M | +9.83% | |
| 2026-06-04 | Sale | Kumar Neil | Chief Executive Officer | 40,000 0.0205% | $67.46 | $2.7M | +9.95% | |
| 2026-05-21 | Sale | Kumar Neil | Chief Executive Officer | 26,103 0.0132% | $69.44 | $1.81M | +1.61% | |
| 2026-05-18 | Sale | Trimarchi Thomas | President and CFO | 13,651 0.0069% | $65.08 | $888,419 | +8.28% | |
| 2026-05-15 | Sale | Scott Randal W. | director | 10,000 0.0052% | $67.15 | $671,456 | +6.62% | |
| 2026-05-08 | Sale | Kumar Neil | Chief Executive Officer | 40,000 0.0203% | $66.91 | $2.68M | +3.41% | |
| 2026-05-07 | Sale | Kumar Neil | Chief Executive Officer | 40,000 0.0208% | $67.90 | $2.72M | +3.30% | |
| 2026-04-30 | Sale | Apuli Maricel | Chief Accounting Officer | 2,000 0.001% | $71.58 | $143,160 | -2.46% |
| Lo Andrew | director | 50583 0.026% | $3.74M | 2 | 3 | <0.0001% |
| Ellis Andrea | director | 22579 0.0116% | $1.67M | 1 | 5 | +16.69% |
| DANIELS RONALD J | director | 16991 0.0087% | $1.26M | 2 | 2 | <0.0001% |
| Scott Randal W. | director | 11589 0.0059% | $857,933.67 | 1 | 9 | |
| Valantine Hannah | director | 9259 0.0048% | $685,443.77 | 2 | 12 | <0.0001% |
| VIKING GLOBAL PERFORMANCE LLC | 10 percent owner | 26620991 13.6657% | $1.97B | 1 | 0 | +6.17% |
| VIKING GLOBAL INVESTORS LP | 10 percent owner | 18555375 9.5253% | $1.37B | 1 | 3 | +6.17% |
| KKR Genetic Disorder L.P. | 10 percent owner | 13260971 6.8074% | $981.71M | 1 | 5 | +7.23% |
| HENDERSON MICHAEL THOMAS | Chief Business Officer | 274211 0.1408% | $20.3M | 1 | 19 | +7.23% |
| STEPHENSON BRIAN C | CFO and Treasurer | 102464 0.0526% | $7.59M | 2 | 30 | +7.23% |
| MOMTAZEE JAMES C | director | 88491 0.0454% | $6.55M | 1 | 0 | <0.0001% |
| Dachille Douglas A. | 20000 0.0103% | $1.48M | 3 | 0 | <0.0001% | |
| Hassan Fred | director | 19300 0.0099% | $1.43M | 1 | 0 | <0.0001% |
| SAUNDERS BRENT L | director | 17600 0.009% | $1.3M | 1 | 0 | <0.0001% |
| Sinha Uma | Chief Scientific Officer | 14000 0.0072% | $1.04M | 1 | 0 | +7.23% |
$961,890,236 | 276 | 22.46% | $23.97B | |
$273,531,368 | 93 | 38.24% | $9.16B | |
$2,765,836 | 72 | 20.00% | $10.77B | |
$108,876,545 | 67 | 72.81% | $14.6B | |
$11,991,408 | 51 | 18.36% | $22.91B |
| Increased Positions | 263 | +61.74% | 24M | +12.75% |
| Decreased Positions | 194 | -45.54% | 20M | -10.52% |
| New Positions | 102 | New | 7M | New |
| Sold Out Positions | 50 | Sold Out | 6M | Sold Out |
| Total Postitions | 495 | +16.2% | 192M | +2.22% |
| Vanguard Group Inc | $1.32M | 8.72% | 16.83M | +347,074 | +2.1% | 2025-09-30 |
| Viking Global Investors Lp | $1.25M | 8.28% | 15.98M | -3M | -13.89% | 2025-09-30 |
| Blackrock, Inc. | $1.13M | 7.47% | 14.41M | +151,724 | +1.06% | 2025-09-30 |
| Kohlberg Kravis Roberts & Co. L.P. | $1.04M | 6.87% | 13.26M | 0 | 0% | 2025-09-30 |
| Janus Henderson Group Plc | $683,858.00 | 4.53% | 8.74M | -535,453 | -5.77% | 2025-09-30 |
| Farallon Capital Management Llc | $640,901.00 | 4.25% | 8.19M | +292,000 | +3.7% | 2025-09-30 |
| Aisling Capital Management Lp | $476,421.00 | 3.16% | 6.09M | +21,486 | +0.35% | 2025-09-30 |
| State Street Corp | $438,612.00 | 2.91% | 5.61M | -290,256 | -4.92% | 2025-09-30 |
| Invesco Ltd. | $307,358.00 | 2.04% | 3.93M | +1M | +40.26% | 2025-09-30 |
| Geode Capital Management, Llc | $305,894.00 | 2.03% | 3.91M | +228,361 | +6.2% | 2025-09-30 |